DDrare: Database of Drug Development for Rare Diseases

Searched query = "Sarcoidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 1% lignocaine; 13NH3 PET/CT scan; 18F-FDG; 18F-FSPG; 18F-fluorodeoxyglucose; 18FDG PET/CT scan; 2% lignocaine; 68Ga-DOTANOC; 68Ga-DOTATATE; 68Ga-DOTATATE PET/CT; 99m technetium infliximab; 99mTc-Infliximab; ABPC; ACT-293987 / JNJ-67896049; ACTHAR Gel (adrenocorticotropic hormone); ACTHAR Gel 40 units twice weekly; ACTHAR Gel 80 units twice weekly.; ACZ885; AMPC; ARA 290; ATYR1923; ATYR1923 1.0 mg/kg; ATYR1923 3.0 mg/kg; ATYR1923 5.0 mg/kg; Abatacept; Acthar; Acthar Gel; Acthar gel; Adalimumab; Adrenocorticotropic hormone; All subjects will receive maraviroc 300mg orally twice a day for 6 weeks; Allogeneic stem cell transplantation; Ambrisentan; Anakinra; Analysis of gamma globulin; Antibiotic Regimen; Antituberculous therapy along with steroids; Armodafinil; Atorvastatin; Autologous hematopoietic stem cell transplantation; Azithromycin; Azithromycin 250Mg Capsule; Azithromycin monohydrate; BAL; Bardoxolone; Bardoxolone methyl; Blood sample; Bosentan; Bosentan monohydrate; C11-methionine; CC; CC-100004; CC-220; CC-220 0.3 mg Daily; CC-220 0.6mg Daily; CMK389; CNTO 148; CNTO1275; CNTO148; Calcium; Calcium Citrate with Vitamin D2; Calcium citrate; Canakinumab; Ciclesonide; Clarithromycin; Corticosteroid; Corticotropin; Cu-64 DOTATATE; Cyclophosphamide; Cysteine; D-methylphenidate; DELTACORTENE*10CPR 25MG; DEXAMETHASONE; DOTANOC; Dapsone; Device: Blood pressure; Device: Flexible bronchoscopy in moderate sedation; Device: Nested PCR for formalin-fixed tissues; Device: Nested PCR for fresh tissues; Device: Oxygen saturation; Device: Propofol dosage; Device: Real-time PCR for fresh tissues; Device: Recovery time after bronchoscopy; Dexamethasone; Dexamethasone 0,5mg; Diagnostic Test: 18F-FDG-PET/MRI; Diagnostic Test: 18F-GE180-PET/MRI; Diagnostic Test: 68Ga-DOTA-TOC PET/CT; Diagnostic Test: FDG-PET/CT with Rb82 Myocardial Perfusion Imaging; Diagnostic Test: Laboratory testing; Diagnostic Test: Spirometry; Diagnostic Test: simultaneous combined 18F-FDG PET and cardiac MRI imaging; Dotatate; Doxycycline; Ergocalciferol; Ethambutol; FDG; FLUORINE (18F) FLUDEOXYGLUCOSE; Fermented oyster extract; Fludeoxyglucose; Fluorodeoxyglucose; Folic acid; Formalin; Ga-68-DOTA-NOC; Gallium-68 DOTATATE; Gallium-68-DOTA-N-Octreotide; Genetic: RNA Sequencing; Glucocorticoid (prednisone or prednisolone); Gold; Golimumab; Golimumab Liquid in prefilled syringe; H.P. Acthar Gel; Habitrol; Heparin; Human anti TNF-alpha monoclonal antibody; Human anti-IL 12/23 monoclonal antibody; Humira; Hydroxychloroquine; Hydroxychloroquine + Prednisone; ILARIS; IMod.Fc, H-Fcv3-N4; Ilaris; Iloprost; Indium; Indium-111 Pentreotide; Infliximab; Influenza Vaccine; Inhaled Treprostinil; L-METHIONINE ([11C]METHYL); L-methionine; Levaquin; Levofloxacin; Lignocaine; Low dose prednisolone; METHOTREXATE; MTX; Maraviroc; Medium dose prednisolone; Methionine; Methotrexate; Methylphenidate; Methylphenidate (overencapsulated); Methylphenidate 10mg tablets; Methylprednisolone; Methylprednisolone bolus IV 15 mg/kg/d for 3 days.; Minomycin; Mycophenolate; N-acetyl-cysteine; Nelutri™; Nicotine; Nicotine patch; None; OCTREOTIDE; ORENCIA; Octreotide; Octreotide LAR / Sandostatin LAR (LAR=long acting release); Orencia; Other: 18F-FDG; Other: 18F-Fluorodeoxyglucose (18F-FDG) PET/CT; Other: Normal Saline for injection; Oxygen; Oyster; PD 0360324; PDA001 (cenplacel-L); PLAQUENIL*25CPR RIV 200MG; PREDNISONE; Pentoxifylline; Pirfenidone; Prednisolone; Prednison; Prednisone; Procedure: Bronchoalveolar lavage (BAL); Procedure: Bronchoscopy with bronchoalveolar lavage; Procedure: EBB + TBLB + BAL; Procedure: EBUS guided transbronchial forceps biopsy (EBUS-TBFB); Procedure: EBUS guided transbronchial needle aspiration (EBUS-TBNA); Procedure: EUS-FNA/EBUS-TBNA + BAL; Procedure: Endobronchial forceps biopsy; Procedure: Skin biopsy; Procedure: large bore (19G) histologic needle biopsy of the mediastinal lymph nodes; Procedure: venipunctures; Propofol; Quercetin; Radiation: Rubidium PET; Rapamune; Remicade; Repository Corticotropin Injection; Repository Corticotropin Injection -Treatment Extension; Rifampin; Rifampin and azithromycin.; Riociguat; Rituximab; Roflumilast; Rubidium; SELEXIPAG; SIROLIMUS; Sandostatin LAR; Sarilumab; Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]_#1; Schisandra chinensis extract; Seasonal influenza vaccine available for the 2012-2013 vaccine campaign; Selexipag; Sirolimus; Sirolimus Ointment; THALIDOMIDE; Tadalafil; Thalidomide; Tofacitinib; Tofacitinib 5 mg twice daily; Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial; Tofacitinib 5mg [Xeljanz] 1 year open-label extension; Tracleer; Tranilast; Treprostinil; Uptravi; Ursodeoxycholic Acid; Ursodeoxycholic acid; Ustekinumab; Ustekinumab liquid in prefilled syringe; Vitamin D2; Water

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2018-000381-11-GB (EUCTR)	09/11/2020	16/06/2020	Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis	A subject and investigator blinded, randomized, placebo-controlled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sarcoidosis	Chronic pulmonary sarcoidosis MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Product Code: CMK389 INN or Proposed INN: CMK389	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	66	Phase 2	United States;Czech Republic;Poland;Denmark;Germany;United Kingdom
2	EUCTR2018-000381-11-PL (EUCTR)	06/10/2020	23/07/2020	Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis	A subject and investigator blinded, randomized, placebo-controlled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sarcoidosis	Chronic pulmonary sarcoidosis MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Product Code: CMK389 INN or Proposed INN: CMK389	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	66	Phase 2	United States;Czech Republic;Poland;Denmark;Germany;United Kingdom
3	NCT04064242 (ClinicalTrials.gov)	September 23, 2020	20/8/2019	Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis	A Subject and Investigator Blinded, Randomized, Placebo-controlled, Repeat-dose, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis	Pulmonary Sarcoidosis	Drug: CMK389;Drug: Placebo	Novartis Pharmaceuticals	NULL	Recruiting	18 Years	65 Years	All	66	Phase 2	United States;Denmark;Germany;Poland
4	EUCTR2018-000381-11-DK (EUCTR)	24/08/2020	30/06/2020	Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis	A subject and investigator blinded, randomized, placebo-controlled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sarcoidosis	Chronic pulmonary sarcoidosis MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Product Code: CMK389 INN or Proposed INN: CMK389	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	66	Phase 2	United States;Czechia;Poland;Denmark;Germany;United Kingdom
5	EUCTR2018-000381-11-DE (EUCTR)	16/06/2020	31/01/2020	Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis	A subject and investigator blinded, randomized, placebo-controlled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sarcoidosis	Chronic pulmonary sarcoidosis MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Product Code: CMK389 INN or Proposed INN: CMK389	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	66	Phase 2	United States;Czech Republic;Poland;Denmark;Germany;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2018-000381-11-GB
(EUCTR)

09/11/2020

16/06/2020

Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis

A subject and investigator blinded, randomized, placebo-controlled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sarcoidosis

Chronic pulmonary sarcoidosis
MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]

Product Code: CMK389
INN or Proposed INN: CMK389

Novartis Pharma AG

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

United States;Czech Republic;Poland;Denmark;Germany;United Kingdom

EUCTR2018-000381-11-PL
(EUCTR)

06/10/2020

23/07/2020

Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis

Product Code: CMK389
INN or Proposed INN: CMK389

Novartis Pharma AG

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

United States;Czech Republic;Poland;Denmark;Germany;United Kingdom

NCT04064242
(ClinicalTrials.gov)

September 23, 2020

20/8/2019

Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis

A Subject and Investigator Blinded, Randomized, Placebo-controlled, Repeat-dose, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis

Pulmonary Sarcoidosis

Drug: CMK389;Drug: Placebo

Novartis Pharmaceuticals

NULL

Recruiting

18 Years

65 Years

All

Phase 2

United States;Denmark;Germany;Poland

EUCTR2018-000381-11-DK
(EUCTR)

24/08/2020

30/06/2020

Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis

Product Code: CMK389
INN or Proposed INN: CMK389

Novartis Pharma AG

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

United States;Czechia;Poland;Denmark;Germany;United Kingdom

EUCTR2018-000381-11-DE
(EUCTR)

16/06/2020

31/01/2020

Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis

Product Code: CMK389
INN or Proposed INN: CMK389

Novartis Pharma AG

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

United States;Czech Republic;Poland;Denmark;Germany;United Kingdom